HLB Life Science Acquires 6 Billion Won of 13th Series Convertible Bonds Before Maturity, Reducing Potential Dilution Risk
HLB Life Science acquired 6 billion won of its 13th series unregistered unsecured private convertible bonds via over-the-counter purchase on June 18, 2026, following an agreement with the bondholder. The total acquisition cost including interest was approximately 6.113 billion won, funded from internal resources.
After the acquisition, the remaining unconverted convertible bonds amount to 6.2 billion won, and the conversion price is 8,008 won. This reduces potential share conversion by approximately 749,000 shares, partially alleviating concerns over dilution of existing shareholder value.
The future treatment of the acquired bonds will be decided by the board in a later meeting, with no further disclosure yet. The company maintains a stable financial structure with a debt-to-equity ratio of 84.55%.
[AI Summary]This early acquisition of convertible bonds, while small in scale, signals a positive step to reduce potential dilution and shows some commitment to protecting shareholder value. However, the use of internal funds results in short-term cash outflow, and the uncertainty regarding future treatment warrants attention to subsequent disclosures.
KOSDAQ Filing Information
Acquisition of Bonds Prior to Maturity Following Issuance of Convertible Bonds (Including Overseas Convertible Bonds) (Series 13)